Produced by the National Institute of Allergy and Infectious Diseases (NIAID), this digitally colorized, scanning electron microscopic (SEM) image shows a clump of yellow-colored, spheroid-shaped Staphylococcus aureus bacteria enmeshed in a blue-colored, filamentous extracellular matrix, which typically binds cells together in various body tissues.
Image credit: National Institute of Allergy and Infectious Diseases (NIAID)
Munich, Germany-based LimmaTech Biologics AG has made significant progress in its mission to combat Staphylococcus aureus infections. The company recently announced that it has vaccinated the first participants in a crucial phase 1 clinical trial of its multivalent vaccine candidate, LBT-SA7.
Developing a vaccine against S. aureus has long been a challenging endeavor due to the bacterium’s ability to evade the immune system. However, LimmaTech believes that LBT-SA7 holds the potential to be a game-changer in preventing skin and soft tissue infections (SSTIs) caused by S. aureus.
“We’re thrilled to launch the first-in-human clinical trial for LBT-SA7, a critical step toward addressing a significant global health challenge,” stated Patricia Martin-Killias, ScD, the Chief Operating Officer of LimmaTech.
FDA Fast Track Designation and CARB-X Award
LimmaTech has received Fast Track designation from the FDA, underscoring the vaccine’s potential to meet an unmet medical need. This designation accelerates the development and review process for drugs that treat serious conditions and fill a crucial gap in medical treatment.
The company has also secured funding of $6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This grant will further advance the clinical development of LBT-SA7.
“CARB-X’s support is vital in our drive to develop efficient solutions for preventing microbial infections,” commented Franz-Werner Haas, PhD, CEO of LimmaTech.
Key Points
LBT-SA7’s phase 1 trial is underway, vaccinating 130 healthy adults aged 18 to 50.
The vaccine has received FDA Fast Track designation, indicating its potential to address a significant medical need.
LimmaTech has received $6.5 million from CARB-X to advance LBT-SA7’s clinical development.
The Urgency of S. aureus Infections
S. aureus, commonly found on human skin and in the nasal passages, can cause a range of infections when it enters the body. These infections range from minor skin irritations to severe conditions such as bloodstream infections, pneumonia, and osteomyelitis.
Methicillin-resistant S. aureus (MRSA) is particularly concerning, often leading to serious or fatal outcomes in healthcare settings. According to the Centers for Disease Control and Prevention (CDC), S. aureus infections result in an estimated 1 million deaths annually, with 90% being community-acquired SSTIs.
S. aureus is also a leading cause of deaths attributed to antimicrobial resistance (AMR), highlighting the critical need for effective preventive measures. LimmaTech’s vaccine represents a promising development in this global health fight.
The Future of LBT-SA7
The phase 1 trial will assess the safety and immunogenicity of LBT-SA7 in 130 healthy adults. If successful, this trial will pave the way for further studies and eventual regulatory approval.
Initial results from this pivotal study are anticipated in the second half of 2025. LimmaTech’s ongoing efforts bring hope to millions affected by S. aureus infections, offering a potential solution to a growing healthcare concern.
Learn More
For those interested in understanding more about clinical care and management of S. aureus infections, visit Contagion Live.
Your Thoughts Matter
We’d love to hear your thoughts on this groundbreaking development. Share your insights below and stay updated on the latest advances in medical research.
Leave your comment or subscribe to our newsletter for more updates.
Don’t forget to share this article with your network and help spread the word.